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Background—Combined analysis of 2 genome-wide association studies in cases enriched for family history recently
identified 7 loci (on 1p13.3, 1q41, 2q36.3, 6q25.1, 9p21, 10q11.21, and 15q22.33) that may affect risk of coronary artery
disease (CAD). Apart from the 9p21 locus, the other loci await substantive replication. Furthermore, the effect of these
loci on CAD risk in a broader range of individuals remains to be determined.
Methods and Results—We undertook association analysis of single nucleotide polymorphisms at each locus with CAD risk
in 11 550 cases and 11 205 controls from 9 European studies. The 9p21.3 locus showed unequivocal association
(rs1333049, combined odds ratio [OR]1.20, 95% CI [1.16 to 1.25], probability value2.811021). We also
confirmed association signals at 1p13.3 (rs599839, OR1.13 [1.08 to 1.19], P1.44107), 1q41 (rs3008621,
OR1.10 [1.04 to 1.17], P1.02103), and 10q11.21 (rs501120, OR1.11 [1.05 to 1.18], P4.34104). The
associations with 6q25.1 (rs6922269, P0.020) and 2q36.3 (rs2943634, P0.032) were borderline and not statistically
significant after correction for multiple testing. The 15q22.33 locus did not replicate. The 10q11.21 locus showed a
possible sex interaction (P0.015), with a significant effect in women (OR1.29 [1.15 to 1.45], P1.86105) but
not men (OR1.03 [0.96 to 1.11], P0.387). There were no other strong interactions of any of the loci with other
traditional risk factors. The loci at 9p21, 1p13.3, 2q36.3, and 10q11.21 acted independently and cumulatively increased
CAD risk by 15% (12% to 18%), per additional risk allele.
ConclusionsThe findings provide strong evidence for association between at least 4 genetic loci and CAD risk.
Cumulatively, these novel loci have a significant impact on risk of CAD at least in European populations. (Arterioscler
Thromb Vasc Biol. 2009;29:774-780.)
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Coronary artery disease (CAD), and its main complica-tion, myocardial infarction (MI), have a significant
genetic basis. Until recently, attempts at identifying genetic
variants that affect risk of these common diseases have been
hampered by poor reproducibility of associations and limited
coverage of the genome.1 However, well-powered genome-
See accompanying article on page 615
wide association (GWA) studies have now identified several
novel putative loci that increase risk of CAD and MI.2–5
Specifically, combined analysis of the Wellcome Trust Case
Control Consortium (WTCCC) and the German MI Family
GWA studies identified 7 chromosomal loci (on 1p13.3,
1q41, 2q36.3, 6.q25.1, 9p21.3, 10q11.21, and 15q22.33), all
of which showed highly significant associations with CAD.5
The locus on chromosome 9p21.3 was also identified in 2
other GWA studies3,4 and has since been associated with
CAD, stroke, as well as abdominal aortic and intracranial
aneurysms in several other cohorts.6–8 The locus on chromo-
some 1p13.3 was recently shown to also be strongly associ-
ated with LDL cholesterol concentration,9–13 reinforcing the
close mechanistic association between the variability in LDL
levels and CAD risk. Beyond these initial studies on the loci
at 9p21.3 and 1p13.3, the reproducibility of the association
with CAD risk of the other loci identified by GWA studies
has not yet been studied systematically.
Many of the exploratory GWA studies were carried out on
patients with a high genetic burden of the disease. For example,
both the WTCCC and German MI Family Study analyzed cases
enriched for a positive family history of CAD.5 Here, in one of
the largest molecular-genetic experiments on CAD, we report
the replication analysis of the 7 principal loci for CAD identified
thus far in GWA studies,2–5 in a broader group of CAD patients,
explore their interactions with traditional risk factors, and assess
their cumulative impact on CAD risk.
Materials and Methods
Study Populations
We investigated participants recruited into 9 separate studies in
Europe with validated cases of CAD and appropriate controls: the
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Academic Medical Center Amsterdam Premature Atherosclerosis
Study (AMC-PAS), the Etude Cas-Te´moins sur l’infarctus du Myo-
carde Study (ECTIM), the European Prospective Investigation into
Cancer and Nutrition Study (EPIC-Norfolk), the German MI Family
Study (GerMIFS; only including subjects that did not overlap with
the original GWA Study), the Cooperative Health Research in the
Region of Augsburg Study (KORA/GOC), the Ludwigshafen Risk
and Cardiovascular Health Study (LURIC), the MORGAM Study,
which has harmonized data from prospective follow-up of population
cohorts in several countries, the Population-based northern German
cross-sectional study (PopGen), and the UKMI Study. Almost all of
these participants were of white Northern European origin. Details of
the recruitment process in each study and references for each study
are provided in the supplemental materials (available online at
http://atvb.ahajournals.org). For the chromosome 9p21.3 locus some
of the study groups (GerMIFS, KORA/GOC, PopGen, and UKMI)
overlap with a previous publication on this locus.6 In addition, the
MORGAM Study has recently reported an analysis of the association
of the novel loci with disease history and risk factors at baseline, and
CAD and stroke events and death during follow-up in their prospec-
tive cohorts.14
Definition of Phenotypes
Common criteria for CAD and MI were applied across all the studies
and required validated evidence for the phenotype (see supplemental
materials). Cases not meeting these criteria were excluded. Similarly,
uniform criteria were defined for partitioning of participants for risk
factors (see supplemental materials). Those individuals where the
information was unavailable or could not be assigned according to
the criteria were classified as missing for the variable.
SNP Selection and Genotyping
For the 7 loci (1p13.3, 1q41, 2q36.3, 6.q25.1, 9p21.3, 10q11.21,
15q22.33), we selected the SNP showing the strongest association
with CAD in the previous GWA analysis (lead SNP).5 In addition,
we selected SNP rs10738610 in the 9p21.3 locus which had shown
marginally stronger association in a fine mapping experiment using
HapMap SNPs,6 and SNP rs2972147 in the 2q36.3 locus which is a
proxy for rs2943634. Finally, linkage disequilibrium analysis of the
7 loci in HapMap identified that in 3 of them, there were subsets of
highly correlated SNPs (r20.8) significantly associated with
CAD/MI which were not in the haplotype block defined by the lead
SNP. The most significant SNP in each of these secondary haplotype
blocks was also selected for genotyping giving a total of 13 SNPs
(supplemental Table I and supplemental Figure I).
Genotyping was carried out with the iPLEX assay (Sequenom) for
all SNPs except rs599839 and rs2943634, which were assayed by
TaqMan (Applied Biosystems) using standard protocols (assays
details available by request from the authors). iPLEX genotyping
was performed at the Wellcome Trust Sanger Institute in Cambridge,
UK, for all studies apart from MORGAM which was genotyped at
the National Public Health Institute, Helsinki, Finland (Sequenom
assay) and INSERM Unit 525, Paris France (TaqMan assays).
Statistical Analyses
Analysis was performed in Stata (Stata Statistical Software Release
10, 2007, StataCorp LP). Each study was analyzed separately by
unconditional logistic regression using an additive genetic model (ie,
genotype codes 0, 1, 2) adjusting for center in studies involving
multiple sites. Heterogeneity between the studies was tested using
Cochran Q chi-squared test, and the size of the heterogeneity was
measured using the I2 statistic. Only one nonlead SNP showed strong
between-study heterogeneity (see supplemental Table III). Conse-
quently, the odds ratios (OR) for the studies were meta-analyzed
under a fixed effect model. Bonferroni correction was used to adjust
for the number of SNPs tested. The analysis was performed for CAD
cases and then for the subset of MI cases. The assumption of an
additive model was assessed in the whole dataset by comparing the
fit of that model with the fit of a 2-degree of freedom pairwise
comparison in a likelihood ratio test. To assess the overall strength of
the association of novel loci with CAD risk, probability values from
the present analysis were combined with those from the GWA
studies5 using Fisher method, both with and without adjusting the
original GWAs findings for multiple comparisons using the Bonfer-
roni method. All tests were 2-sided.
To investigate whether there was any interaction between a locus
and relevant demographic characteristics or cardiovascular risk
factors (age, sex, body mass index, hypertension, smoking, and
diabetes) participants were divided into 2 groups on the basis of the
particular covariate. The analysis for CAD was repeated on the
appropriate selection of patients in the same way as for the full study,
and then the results were combined into a single forest plot.
Independent effects of the associated loci were verified by
including them all in a single logistic regression. Cumulative risk
was assessed by forming a score based on the total number of risk
alleles across 4 or 6 loci (see Results). The case/control status was
then compared with the number of risk alleles in a logistic regression
analysis adjusting for study and center within study. The number of
risk alleles was considered both as a categorical measure and as a
continuous measure in a trend test.
Power calculations were performed by simulation. Data were
generated to represent studies of the same numbers of cases and
controls as in the actual replication study using an additive model
with a given common odds ratio and allele frequency and assuming
Hardy-Weinberg equilibrium (HWE). Analysis was by logistic
regression and then meta-analysis as in the main study. The number
of individual studies that were significant at the 5% level was
counted and whether the combined result was significant was noted.
Each set of simulations was repeated 1000 times.
Results
Study Participants
The characteristics of the pooled case and control participants
from the 9 European studies are shown in Table 1. Addition-
ally, the characteristics of participants in each study individ-
ually are shown in supplemental Table II. Altogether, 22 755
participants (11 550 cases and 11 205 controls) underwent
genotyping from these studies. As anticipated, the prevalence
of established cardiovascular risk factors was higher in CAD
cases than in controls (Table 1). Of the CAD cases, 6831
(59.1%) had a confirmed history of MI and the mean age of
cases at first event was 59.5 (std. dev. 10.0) years.
Table 1. Summary Characteristics of Participants Included in
the Study
Cases Controls
No. 11 550 11 205
Males, % 79% 63%
Age (years), mean (SD) 59.5 (10.0) 55.9 (12.8)
BMI (kg/m2), mean (SD) 27.6 (4.2) 26.6 (4.2)
Hypertension 58% 28%
Ever smoked 74% 62%
Diabetes 16% 4%
MI 59%
The characteristics of the cases and controls in the 9 individual studies are
shown in supplemental Table II. Definitions for hypertension, smoking, and
diabetes are given in the supplemental materials. For cases the age given and
the status for hypertension, diabetes, and smoking relate to the time of event
or at time of recruitment for the prospectively ascertained studies (EPIC-Norfolk
and MORGAM). Data on risk factors were unavailable for 3 of the control
cohorts (see supplemental Table II).
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Association Analysis
Genotypes in excess of 90% were obtained for all SNPs, and
there was no difference in the proportion of successful
genotypes between cases and controls (supplemental Table I).
None of the SNPs showed significant deviation from HWE.
Nominally significant association (P0.05) with CAD was
observed at 6 of the 7 chromosomal loci studied (Table 2).
For all loci, except for chromosome 1q41, the lead SNP
identified in the GWA studies5 showed the strongest associ-
ation among the genotyped SNPs (supplemental Table III).
Moreover, in all instances the same allele as in the previous
study showed the increased risk with CAD. Interestingly, for
1q41, no significant association was seen for the previously
reported lead SNP (rs17465637; supplemental Table III);
however, a SNP (rs3008621) in an adjacent haplotype block
showed a significant association (Table 2). The strength of
the association ranged from an OR of 1.20 (95% CI: 1.16 to
1.25) for the 9p21 locus (rs1333049, P1.631021) to an
OR of 1.05 (1.00 to 1.09) for the locus at 2q36.3 (rs2943634,
P0.03) and 1.05 (1.01 to 1.10) for the locus at 6q25.1
(rs6922269 P0.02). The associations for the loci at 2q36.3
and 6q25.1 were not statistically significant after Bonferroni
correction for the number of SNPs tested (Table 2). We found
no evidence for association with the locus at 15q22.33 (Table
2). The associations in the subset of cases with MI largely
paralleled those seen for CAD (Table 2).
To examine the totality of our evidence of association for
each locus, we also combined the association results from the
present studies with those from the 2 original GWA studies.5
The signals for the 6 loci that showed nominally significant
association in the present study became stronger in a meta-
analysis that included these prior studies, even after correc-
tion for multiple testing in the GWA studies (supplemental
Table IV). There was no evidence of nonadditivity for any of
the loci assessed (ie, better fit using a dominant or recessive
model: supplemental Table V).
Heterogeneity and Interactions
There was no significant heterogeneity in the magnitude of
the associations of the loci between the pooled studies (Table
2). However, as expected from the power calculations (see
Methods and supplemental Table VI), associations were not
individually significant in every study (findings for each
study by locus are shown in supplemental Figure II).
We also investigated whether there was any interaction
between the effect of the loci and a number of prespecified
characteristics or risk factors, namely age, sex, BMI, hyper-
tension, diabetes mellitus, and smoking on risk of CAD. The
analyses are displayed in supplemental Figure III. Note that
the analyses for the risk factors are limited because only
demographic information (age and sex) was available from 3
of the control groups (supplemental Table II). The most
notable finding was that the magnitude of the association
of the locus on 10q11.21 with CAD was greater (P0.015
for interaction) in women (OR1.29 [1.15 to 1.45],
P1.86105) compared with men (OR1.03 [0.96 to
1.11], P0.387). There was also a suggestion that the effect
of the locus on 1q41 was only present in older subjects and
that the effect of the chromosome 9p21 locus was stronger in
women and weaker in the presence of hypertension. How-
ever, neither of these interactions was significant (P0.05),
and otherwise the association of the loci with CAD appeared
largely independent of anthropometric characteristics and risk
factors (supplemental Figure III).
Distribution of Risk Alleles and Cumulative Risk
The proportions of cases and controls carrying different
number of copies of the risk alleles for the 4 most strongly
associated loci (1p13.3, 1q41, 9p21, and 10q11.21) are shown
in the Figure. There is a significant rightward shift in the
number of risk alleles carried by cases (P0.0001). Because
of the high prevalence of these alleles, the majority of these
European white individuals carry more than 5 out of a
possible 8 alleles (Figure). To investigate the cumulative risk
associated with carriage of multiple risk alleles, we estimated
the ORs in individuals carrying different numbers of the risk
alleles for these loci. The 4 loci act independently with a
combined OR of 1.15 (1.12 to 1.18) per additional risk allele.
Because of the sex-specific effect of the locus on 10q11.21,
the OR per additional risk allele was higher in women (1.21
[1.15 to 1.27]) compared with men (1.12 [1.08 to 1.16]).
There was no significant interaction with age (P0.30).
Table 2. Pooled Association Results for the Lead SNP* at Each Locus for CAD and Separately for MI
CAD MI
SNP Chr
Alleles
a1/a2 RA
MAF in
Controls
MAF in
Cases OR (95% CI) P Value
Hetero
P Value§ OR (95% CI) P Value
Hetero
P Value§
rs599839 1p13.3 A/G A 0.228 0.207 1.13 (1.08, 1.19) 1.44107 (1.87106) 0.72 1.11 (1.05, 1.18) 2.35104 (3.06103) 0.38
rs3008621* 1q41 G/A G 0.136 0.122 1.10 (1.04, 1.17) 1.02103 (1.3310-2) 0.49 1.09 (1.01, 1.17) 2.11102 (0.274) 0.24
rs2943634 2q36.3 C/A C 0.342 0.333 1.05 (1.00, 1.09) 3.22102 (0.419) 0.24 1.03 (0.98, 1.09) 0.218 (1.000) 0.24
rs6922269 6q25.1 G/A A 0.263 0.272 1.05 (1.01, 1.10) 1.96102 (0.255) 0.40 1.08 (1.03, 1.14) 3.45103 (4.49102) 0.66
rs1333049 9p21 G/C C 0.458 0.505 1.20 (1.16, 1.25) 2.891021 (3.761020) 0.65 1.24 (1.18, 1.30) 1.281018 (1.661017) 0.76
rs501120 10q11.21 T/C T 0.133 0.121 1.11 (1.05, 1.18) 4.34104 (5.64103) 0.04 1.15 (1.07, 1.24) 1.99104 (2.59103) 0.07
rs17228212 15q22.33 T/C C 0.276 0.274 1.00 (0.95, 1.04) 0.893 (1.000) 0.11 1.02 (0.97, 1.07) 0.521 (1.000) 0.13
*Lead SNP refers to the SNP that showed the strongest association at each locus in the prior genome-wide association studies except for chromosome 1q41 where
the findings relate to a related SNP (see Text). a2 is minor allele. §P value for heterogeneity between studies assessed (see Statistical Methods). SNP indicates
single nucleotide polymorphism; chr, chromosome, RA, risk allele; MAF, minor allele frequency; OR, odds ratio associated with the risk allele; CI, confidence intervals.
The P values in brackets for the odds-ratios are those after Bonferroni correction for the 13 SNPs that were tested (see Methods and supplemental Table I). The CIs
have not been adjusted for multiple comparisons.
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Discussion
In this study we describe a large scale evaluation of novel loci
for CAD identified through previous GWA studies.5 In
addition to the 9p21 locus, which has already been robustly
replicated in several other studies,2,3,6–8 we provide compel-
ling evidence for the association of at least 3 further loci
(1p13.3, 1q41, and 10q11.21) with CAD risk. Nominal
associations (P0.05) were observed for 2 further loci, those
at 2q36.3 and 6q25.1, but these became statistically nonsig-
nificant after correction for the number of variants examined.
The increase in risk among the loci ranged from 5% to 20%
per copy of the risk allele. These are less than those we found
in the GWA studies (20% to 37%).5 There are perhaps two
main reasons for this. First, the GWA studies were carried out
in relatively young cases enriched for a genetic tendency for
CAD (each case had to have at least one first degree relative
affected with CAD) which may have enhanced the genetic
effect. Second, primary association findings by their nature
tend to often be more inflated than the true degree of
association. Thus, some degree of “the winner’s curse” was to
be expected.15 Our present analysis was carried out in a much
wider range of individuals with CAD, better reflecting the
disease spectrum with regard to age of onset as well as
relevant comorbidities and thus likely to provide a more
reliable estimate of the association of each locus with CAD
risk in general populations. Although individually the effect
of carrying each risk allele is relatively modest, their impor-
tance in terms of contribution to the development of CAD and
the public health needs to also take into account the preva-
lence of the risk alleles which range from 26% to 87% (Table
2). Thus, most European individuals carry multiple risk
alleles (Figure).
Our study emphasizes the scale of endeavor required to
quantify reliably the modest effect sizes which are typically
being found for loci detected using GWA approaches for
complex traits. Even with a combined sample size of more
than 22 000 European participants, we only had sufficient
(80%) power to detect OR 1.05 across a range of allele
frequencies (supplemental Table VI); hence the evidence of
association for 2 of the loci (those at 2q36.3 and 6q25.1)
remains inconclusive. Furthermore, simulations showed that
even under the most favorable scenario, that pertaining to the
locus at 9p21 with an OR of 1.20 and an allele frequency
approaching 0.5, a “true” effect would not have been ex-
pected to be observed in each of the individual studies.
Indeed, for the sizes of the studies involved here, the
proportion of positive studies we observed for each locus was
largely consistent with what might have been expected for
“true” effects (supplemental Table VI). These findings are
therefore remarkable in that we were able to detect a definite
association with at least four of the initial 7 loci that emerged
from the GWA studies in populations based in geographically
and culturally different parts of Europe. This suggests that
further loci with similar effect sizes await discovery in even
larger analyses. Although we cannot rule out important
gene–gene or gene–environment effects, our findings sug-
gest that the loci identified affect CAD risk under a wide
range of circumstances. This is also consistent with the lack
of significant interactions with demographic parameters or
other cardiovascular risk factors except for the locus on
chromosome 10q11.21 (see below).
Our study does not identify the precise causal variant(s) at
each locus. This will require resequencing of the entire
recombination interval for each locus in a large set of
chromosomes enriched for the risk allele to define the full
spectrum of variants followed by fine mapping of the asso-
ciation signal. The finding at the locus on chromosome 1q41
emphasizes the importance of this work. We confirmed an
association not with the GWA lead SNP but a related SNP
suggesting that both markers are in linkage disequilibrium
(LD) with the causal variant(s) at this locus but the strength
of pair-wise LD differs.
So what are the implications of the present findings? The
role in disease prediction often dominates discussion of such
findings. Our analysis shows that although, cumulatively,
carriage of increasing number of risk alleles imparts substan-
tial additional risk (eg, carriage of seven risk alleles versus 4
risk alleles increases risk on average by 52%), genetic testing
for the 4 most strongly replicated loci is unlikely to be
sufficiently discriminatory to identify people likely to de-
velop CAD (Figure). This lack of discriminatory capability is
very similar to that seen for genetic loci underlying other
complex traits such as diabetes16 as well as with other
cardiovascular risk factors (eg, plasma cholesterol level)17
and consistent with theoretical considerations.18 Potentially a
more immediate and realistic clinical application of the
findings could be to help identify people at increased coro-
nary risk so that primary preventive measures, eg, choles-
terol lowering, could be directed to those at highest genetic
risk. This stratification could theoretically be carried out
from a relatively young age, as DNA analysis can be done
at any stage from birth. However, whether such testing is
clinically beneficial and cost-effective requires much fur-
ther investigation.
Perhaps, the greatest utility of these findings will come
from understanding the mechanisms and pathways by which
Figure. Distribution of cases (dark gray) and controls (light gray)
carrying different number of risk alleles, ranging from 0 to 8, for
the 4 most strongly associated loci: those on 1p13.3, 1q41,
9p21, and 10q11.21. Note the rightward shift in the distribution
for the cases.
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the loci affect CAD risk as this could provide new targets for
drug development. The genes located within each locus
(Table 3) have not been previously implicated in the patho-
genesis of CAD. Recently, for the locus at 1p13.3, the same
allele of SNP rs599839 that is associated with increased CAD
risk, has been shown to be associated with higher plasma total
and LDL cholesterol in multiple studies,9–13 providing a
possible explanation for the effect on CAD risk, although
even for it the precise mechanism by which the locus affects
LDL cholesterol and the gene(s) involved awaits elucida-
tion.19 The 9p21 locus shows a region of association coinci-
dent with a gene for a noncoding RNA, ANRIL.20 Such
RNAs often play a regulatory role in gene expression or
translation. There is preliminary evidence that ANRIL may
affect the expression of the adjacent cyclin-dependent kinase
inhibitors,20 which in turn could affect vascular remodeling
processes which are important in the pathogenesis of athero-
sclerosis and its complications. The association signal at 1q41
lies within the melanoma inhibitory activity family, member
3 (MIA3) gene, which may play a similar role in cell growth
or inhibition.21 The locus at 10q11.21 lies upstream of the
CXCL12 gene which codes for stromal cell-derived factor-1
(SDF-1), a chemokine which plays a key role in stem-cell
homing and tissue regeneration in ischemic cardiomyopathy22
and in promoting angiogenesis through recruitment of endo-
thelial progenitor cells.23 Altogether, the findings open up the
prospect of novel therapies for CAD, which may be broadly
applicable, from a better understanding of the pathogenic
mechanisms in the vascular wall affected by these loci.
Women are less prone to CAD than men, which could
partly be attributable to differences in gene– environment
interactions. Interestingly, the locus on chromosome
10q11.21 showed a stronger association in women than in
men. The nature of the locus with CXCL12 as the most
proximate gene (Table 3) does not suggest an immediate
mechanism that could explain a gender interaction and
whether this finding, which was of borderline statistical
significance and would not have been significant if we had
adjusted for the multiple interaction analyses carried out,
represents a true sex difference in effect requires further
investigation. Apart from this, we did not find any other
striking interactions, although it should be noted that the
lack of data on some risk factors for three control popu-
lations means that our ability to detect such interactions
was constrained and further investigation in a larger
sample is necessary.
In summary, through a large scale replication study we
provide compelling evidence for the association of at least 4
genetic loci and risk for CAD. The findings provide a strong
foundation for further investigation of these loci as risk
factors for CAD and their potential value in the treatment and
prevention of this common condition.
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1p13.3 PSRC1, CELRS2, MYBPHL, SORT1
1q41 MIA3
2q36.3 No recognized genes
6q25.1 MTHFD1L
9p21 p16/CDKN2A, p15/CDKN2B, p14/ARF, MTAP, ANRIL
10q11.21 CXCL12
PSRC1 indicates proline/serine-rich coiled coil 1 gene; CELSR2, cadherin
EGF LAG seven-pass G-type receptor 2 gene; MYBPHL, myosin binding protein
H-like gene; SORT1, sortilin 1 gene; MIA3, melanoma inhibitory activity family,
member 3 (MIA3) gene; MTHFD1L, methylenetetrahydrofolate dehydrogenase
(NADPdependent) 1-like gene; p16/CDKN2A, cyclin-dependent kinase inhib-
itor 2A gene; p15/CDKN2B, cyclin-dependent kinase inhibitor 2B gene;
p14/ARF, P14 tumour suppressor gene; MTAP, methylthioadenosine phosphor-
ylase gene; ANRIL, antisense noncoding RNA; CXCL12, chemokine (C-X-C
motif) ligand 12 gene.
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Supplementary Materials 
 
1. Descriptions of individuals and recruitment procedures by study 
AMC-PAS. Cases were recruited as part of a prospective cohort study (Academic 
Medical Centre Amsterdam Premature Atherosclerosis Study (AMC-PAS) with 
symptomatic CAD before the age of 51 years, defined as MI, coronary 
revascularization, or evidence of at least 70% stenosis in a major epicardial artery.1 A 
collection of DNA samples from blood donors from the north-west region of the 
Netherlands was established as controls for this study. Participating donors were 
recruited at routine Sanquin Blood Bank donation sessions (Sanquin Common 
Controls (SANQUIN-CC). More than 95% of the controls are from the same region as 
the cases of the AMC-PAS cohort. 
 
ECTIM. The ECTIM (Etude Cas-Témoin sur l'Infarctus du Myocarde) study is a case-
control study of MI based on the WHO MONICA (Multinational MONItoring of trends 
and determinants in CArdiovascular disease) Project registers in the United-Kingdom 
(UK) and France2,3. All participants were of European descent and gave an informed 
consent. The recruitment was performed in two phases: in 1988-1990, men with MI, 
aged 25-64 yrs, were drawn from the MONICA registers of Belfast (Northern Ireland), 
Strasbourg, Lille and Toulouse (France). They were recruited 3 to 9 months after the 
event and had to satisfy the WHO MONICA criteria for definite acute MI. In each 
 2 
centre, controls of similar age and sex were randomly selected in the areas covered 
by the MONICA registers. Controls with self-reported history of coronary heart 
disease were excluded from the current analysis. They were drawn from the lists of 
General Practitioners held by the Central Service Agency in Northern Ireland and 
from the electoral rolls in France. In 1997-1998, men and women from Glasgow were 
included in the study using the same protocol. At the same time, the sample was 
extended in Belfast by the inclusion of women and additional men.  
 
EPIC-Norfolk. Participants for this study were from the Norfolk cohort of the 
European Prospective Investigation into Cancer and Nutrition study (EPIC-Norfolk). 
EPIC-Norfolk is a prospective population study of 25 663 men and women aged 
between 40 and 79 years, resident in Norfolk, UK, recruited from general practice 
registers between 1993 and 1997. It is an ethnically homogeneous Caucasian 
population. These participants completed a health examination. Details of 
recruitment, anthropometric measurements, and health examinations following 
standardized protocols have been published.4 All individuals have been flagged for 
death certification at the UK Office of National Statistics, with vital status ascertained 
for the entire cohort. In addition, participants admitted to hospital were identified 
using their unique National Health Service number by data linkage with ENCORE 
(East Norfolk Health Authority database), which identifies all hospital contacts 
throughout England and Wales for Norfolk residents. The Norwich District Health 
Authority Ethics Committee approved the study. All participants gave signed informed 
consent. 
 
 3 
For the purposes of this study, we used a nested case–control design based on 
participants who were disease-free at the baseline assessment. Details of the study 
design have been previously described.5 This study represents an extended follow-
up. Briefly, we excluded all individuals who reported a history of heart attack or stroke 
at the baseline clinic visit. Cases were individuals who developed a fatal or non-fatal 
CAD during an average follow-up of 11 years, until June 2006. Participants were 
identified as having CAD during follow-up if they had a hospital admission and/or 
died with CAD as the underlying cause. CAD was defined as cause of death codes 
ICD9 410-414 or ICD10 I20-I25, and hospital discharge codes ICD10 I20.0, I21, I22 
or I23 according to the International Classification of Diseases, 9th and 10th revisions. 
Controls were study participants who remained free of any cardiovascular disease 
during follow-up (defined as ICD9 401-448 and ICD10 I10-I79). We matched one 
control to each case by sex, age (within 5 years), and time of enrolment (within 3 
months). 
 
GerMIFS. The German MI Family Study (GerMIFS) comprises unrelated German MI 
patients (age of onset < 65 years) having at least one first-degree relative with 
premature CAD.6 The subjects used in this analysis are distinct from those used in 
the initial genome-wide association study.7 Patients were recruited between 1997 
and 2002 from hospital clinics and were studied by physical examination, blood 
testing, echocardiography, as well as a standardized interview. All events were 
validated through inspection of hospital charts. Healthy German married-in spouses 
from the same recruitment centre served as controls.7 
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KORA/GOC. In 1996, a total of 589 patients with history of sporadic MI prior to the 
age of 60 years were identified through the Augsburg, Germany, MONICA MI register 
and recruited. This cohort is referred to as the KORA-B cohort.8 Diagnosis of MI was 
established according to the MONICA diagnostic criteria. From 2007, this cohort has 
been extended by additional patients attending for angiography in the Cardiology 
Department at the University of Regensburg, who also have a validated diagnosis of 
MI prior to 60 years of age Recruitment of this cohort called Go-Kard (GOC) is on-
going. Controls (KORA-S4) represent a gender- and age-stratified random sample of 
all German residents and come from the same geographic area as the cases. They 
participated in the echocardiographic sub study of the third MONICA Augsburg 
survey 1994/1995.9 All controls were recruited with the same protocol as the MI 
patients.  
 
LURIC. The LURIC (Ludwigshafen Risk and Cardiovascular Health) study included 
3,316 consecutive white patients of German ancestry hospitalized for coronary 
angiography between June 1997 and May 2001 in Ludwigshafen, Germany.10 For the 
purpose of this analysis, only subjects with angiographically confirmed CAD (at least 
one coronary vessel with a stenosis > 50%) were included. The controls were from 
the GerBS control series that consists of healthy, unrelated blood donors. They were 
recruited between May-July 2004 from the southwestern area of Germany which 
corresponds to the geographical origin of the LURIC patients by the Institute of 
Transfusion Medicine and Immunology, Mannheim, Germany. According to the 
German guidelines for blood donation all blood donors were examined to rule out 
cardiovascular, malignant, and other diseases by a standard questionnaire, cardiac 
auscultation, blood pressure and pulse measurement.  
 5 
 
MORGAM. MORGAM is a prospective follow-up of the respondents of representative 
population samples that were examined at baseline.11 This study includes cohorts 
from Finland (FINRISK, ATBC), France (Lille, Strasbourg, Toulouse), Northern 
Sweden and UK (Belfast). Details of each cohort and the diagnostic procedures and 
a quality assessment of the baseline and follow-up data in each cohort have been 
published separately.12,13 For its genetic component, MORGAM has a case-cohort 
design.14 For the purposes of this study, cases and controls were selected from the 
MORGAM case-cohort set in such a way that the sets of cases and controls from 
each cohort would be similar in size and comparable with respect to age and sex. For 
each sex in each cohort, the cases and controls were selected using a stepwise 
procedure, starting from the youngest case. A person was eligible to be a case if: (i) 
he had a documented MI at baseline or had definite AMI, unstable angina, cardiac 
revascularization or unclassifiable death during follow-up; and (ii) had not been 
selected as a control for a younger case. A control was selected for each case in 
random from those who were at risk at the age of the onset of the event (or age at 
baseline if the case had a MI at baseline). The risk set, from which the controls were 
selected, constituted of those members of the random subcohort of the MORGAM 
case-cohort set who: (i) had not had documented or self-reported MI or stroke at 
baseline; and (ii) had not had definite or possible AMI, unstable angina or cardiac 
revascularization during follow-up before the age of the case; and (iii) were in the 
follow-up at the age of the case; and (iv) had not been selected as a case or a control 
at an earlier stage.  
 
 6 
PopGen. The case sample comprised unrelated CAD patients who were recruited in 
Schleswig-Holstein, the northernmost region in Germany through the population-
based PopGen biobank (www.popgen.de).15 Coronary angiograms of any of the five 
cardiac catheterization laboratories in this geographical area were screened. Study 
subjects were required to demonstrate significant CAD (> 70% stenosis in at least 
one major epicardial coronary vessel). All subjects were recruited between 2002 and 
2005. The control samples were healthy blood donors to the Blood Service of the 
University Hospital Schleswig-Holstein. All subjects were recruited between 2003 and 
2006.  
 
UKMI. The UK MI Study combined subjects from two previous molecular genetic 
studies of MI that were recruited between 1993 and 2002.16,17 The first study16 
comprised 548 consecutive acute MI cases (age < 75 years) recruited from 
admissions to the coronary care units (CCUs) of the Leicester Royal Infirmary, 
Leicester and the Royal Hallamshire Hospital, Sheffield. Control subjects (n = 525) 
were recruited in each hospital from adult visitors to patients without overt CHD and 
were matched for age and gender with the cases. The second study17 comprised 433 
subjects. The MI cases (n = 224) were recruited retrospectively from the registries of 
CCUs in Leicester. All cases satisfied the WHO MONICA diagnostic criteria for acute 
MI. Control subjects (n = 209) were recruited from three primary care practices 
located within the same geographical area as the cases.  
 
2. Definitions  
Because of different recruitment strategies in the different studies and different time 
periods for recruitment (ranging from early 1990s to 2007), during which the definition 
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of MI has changed, a sub-committee of the steering committee consisting of 
clinicians with cardiology experience and an epidemiologist with experience on 
harmonization of data from different studies (CH, HS, KK, NJS) examined the 
definitions used in each study for both CAD phenotypes and risk factors and ensured 
that there was consistency across the studies. Cases that did not meet the criteria for 
CAD or MI were excluded. 
 
(i) Coronary artery phenotypes 
Coronary artery disease (CAD) This was defined by one of the following criteria:  
 Confirmed MI (see below) 
 > 50% stenosis in at least one coronary vessel at angiography with validation 
from hospital records 
 validated history of percutaneous transluminal coronary angioplasty (PTCA) or 
coronary artery bypass graft surgery (CABG) 
  validated angina, defined as symptoms + confirmation from at least non-
invasive provocation test e.g. scintigraphy or exercise treadmill test.  
 For EPIC-Norfolk and MORGAM death confirmed to be due to CAD or highly 
likely to be due to CAD 
 
Myocardial infarction (MI)  Before inclusion, cases with MI in each study had to fulfil 
one of the following criteria:  
1) 'Definite MI' according to the 1983 WHO criteria (―MONICA‖)18 
2) 'MI' according to the ESC/ACC 2000 definition of MI19  
 3) 'Definite MI' according to the 2003 AHA/WHF/ESC/CDC/NHLBI definition20 
 8 
 4) 'Clinical MI' according to the 2004 British Cardiac Society Working Group 
Definition21 
5) 'Myocardial infarction' according to the 2007 ESC/ACCF/AHA/WHF definition.22  
 
(ii). Risk factors 
Risk factors were defined on the criteria defined below. For cases the categorisation 
was based on status at the time of the qualifying event, or at baseline of the 
prospective cohorts (EPIC-Norfolk, MORGAM): 
 Hypertension: Reported history of hypertension or, when such information was not 
available, systolic blood pressure >= 140 mmHg and/or diastolic blood pressure >= 
90 mmHg.  
Diabetes Mellitus. Known Diabetes Mellitus (either Type 1 or Type 2)..  
Smoking Current or former smokers were categorised as smokers; non-smokers 
were subjects who had never smoked. 
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Figure legends 
Figure 1. Linkage disequilibrium (LD) plots of (a) 1q41, (b) 2q36.3, (c) 6q25.1, (d) 
9p21, and (e) 10q11.21 each showing the position of the lead SNP (red circle or 
diamond) and additional ones (blue circles) selected for genotyping.  
 
Figure 2. Forest plots showing the association with CAD in the individual contributing 
studies for the loci on chromosomes 1p13.3, 1q41, 2q36.3, 6q25.1, 9p21, and 
10q11.21. The non-significant results for the locus on chromosome 15q22.33 are not 
shown. The individual odds ratios (OR) with 95% confidence intervals are shown at 
the side of each study. Please refer to text for details of each study. 
 
Figure 3. Forest plots showing the association with CAD for the loci on 
chromosomes 1p13.3, 1q41, 2q36.3, 6q25.1, 9p21, and 10q11.21 for pre-specified 
sub-groups.  The individual odds ratios (OR) with 95% confidence intervals are 
shown at the side of each sub-group. Note the significant difference in the effect of 
the locus on chromosome 10q11.21 between men and women. 
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Supplementary Table 1 List of SNPs genotyped and relationship of additional SNPs typed to the lead SNPs 
 
SNP Chromosome Type* Controls CAD cases MAF in 
controls 
MAF in CAD 
cases 
r
2
 to lead 
SNP 
(controls) 
D’ to lead 
SNP 
(controls) 
rs599839 1p13.3 Lead 10938 11168 0.228 0.207   
rs17465637 1q41 Lead 10708 10878 0.266 0.255   
rs3008621 1q41 additional 10574 10890 0.136 0.122 0.34 0.88 
rs2943634 2q36.3 Lead 10824 11040 0.342 0.333   
rs2972147 2q36.3 additional 10540 10261 0.362 0.354 0.65 0.85 
rs6922269 6q25.1 Lead 10765 11115 0.263 0.272   
rs12214306 6q25.1 additional 10903 11239 0.035 0.034 0.01 0.63 
rs12525353 6q25.1 additional 10852 11194 0.029 0.029 0.01 0.86 
rs1333049 9p21 Lead 10870 11064 0.458 0.505   
rs10738610 9p21 additional 10368 10418 0.475 0.516 0.88 0.98 
rs501120 10q11.21 Lead 10095 10478 0.133 0.121   
rs2146807 10q11.21 additional 10803 11128 0.122 0.117 0.16 0.43 
rs17228212 15q22.33 Lead 10834 11212 0.276 0.274   
 
*Lead SNP is the SNP at each locus showing the strongest association in the combined analysis of the two genome-wide association studies 
(Supplementary Reference 6). The rationale for typing the additional SNPs is given in the main paper (see Methods). r2 and D’ are the two measures of 
linkage disequilibrium between  the lead SNP and the additional SNPs. The number of controls and CAD cases with successful genotypes are shown for 
each SNP as are the minor allele frequencies (MAF) in controls and cases. 
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Supplementary Table 2 Characteristics of the cases and controls in each study 
 
Study  Number Male (%) Age 
Mean (sd) 
BMI 
Mean (sd) 
Hypertension 
(%) 
Smoking 
(%) 
Diabetes 
(%) 
AMC-PAS Cases 744 78% 43.0( 5.2) 27.1(4.1) 27% 76% 10% 
 Controls 1299 67% 50.9( 11.8) - - - - 
ECTIM Cases 1146 78% 55.5( 8.3) 27.0(4.2) 44% 80% 13% 
 Controls 1102 78% 55.7( 8.5) 26.8(4.2) 29% 62% 6% 
EPIC-NORFOLK Cases 1081 69% 65.0( 8.2) 27.1(3.9) 27% 72% 6% 
 Controls 2175 65% 64.4( 7.9) 26.4(3.5) 13% 59% 2% 
GERMAN MI-FS Cases 732 75% 58.6( 8.5) 27.6(4.2) 84% 57% 19% 
 Controls 739 49% 57.4(10.0) 26.8(4.0) 51% 54% 6% 
KORA/GOC Cases 809 84% 59.8( 9.5) 28.3(4.0) 94% 73% 20% 
 Controls 1022 77% 58.3( 9.9) 28.1(4.4)     45% 62% 7% 
LURIC Cases 2038 76% 63.3(10.0) 27.4(4.0) 61% 71% 21% 
 Controls 1334 50% 46.8(15.3) - - - - 
MORGAM Cases 1418 89% 60.4( 7.4) 27.9(4.2) 49% 82% 13% 
 Controls 1433 89% 60.2 ( 7.4) 27.0(4.1) 37% 73% 14% 
POPGEN Cases 2811 82% 60.9( 8.4) 28.0(4.2) 74% 73% 20% 
 Controls 1368 27% 49.2(17.0) 25.5(4.8) - - - 
UKMI Cases 771 73% 54.4(11.1) 27.2(4.8) 31% 80% 9% 
 Controls 733 69% 52.1(10.4) 26.0(3.7) 14% 59% 2% 
 
The number of case and controls in each study and their characteristics are shown. For cases, the age given and the status for hypertension, diabetes 
and smoking relate to the time of event or at time of recruitment for the prospectively ascertained studies (EPIC-Norfolk and MORGAM). See text for 
definition of phenotype. Please note that because the controls for the AMC-PAS, LURIC, and Popgen studies are from blood donor collections there is no 
information on them on cardiovascular risk factors. 
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Supplementary Table 3 Associations in the pooled European cohorts for all SNPs. 
  
      CAD MI 
SNP Chr a1/a2+ RA MAF in controls MAF in cases OR (95%CI) P-value Hetero 
P-value* 
OR (95%CI)  P-value Hetero 
p-value* 
rs599839 1p13.3 A/G A 0.228 0.207 1.13 
(1.08,1.19) 
1.44x10
-7
 
(1.87x10
-6
) 
0.72 1.11 
(1.05,1.18) 
2.35x10
-4
 
(3.06x10
-3
) 
0.38 
rs3008621 1q41 G/A G 0.136 0.122 1.10 
(1.04,1.17) 
1.02x10
-3
 
(1.33x10
-2
) 
0.49 1.09 
(1.01,1.17) 
2.11x10
-2
 
(0.274) 
0.24 
rs17465637 1q41 C/A C 0.266 0.255 1.04 
(0.99,1.09) 
0.089 
(1.000) 
0.43 1.01 
(0.96,1.07) 
0.637 
(1.000) 
0.36 
rs2943634 2q36.3 C/A C 0.342 0.333 1.05 
(1.00,1.09) 
3.22x10
-2
 
(0.419) 
0.24 1.03 
(0.98,1.09) 
0.218 
(1.000) 
0.24 
rs2972147
#
 2q36.3 C/T C 0.362 0.354 1.04 
(1.00,1.09) 
4.29x10
-2
 
(0.558) 
   <0.001 1.03 
(0.98,1.08) 
0.344 
(1.000) 
0.001 
rs6922269 6q25.1 G/A A 0.263 0.272 1.05 
(1.01,1.10) 
1.96x10
-2
 
(0.255) 
0.40 1.08 
(1.03,1.14) 
3.45x10
-3
 
(4.49x10
-2
) 
0.66 
rs12214306 6q25.1 T/C T 0.035 0.034 1.04 
(0.94,1.15) 
0.474 
(1.000) 
0.52 1.04 
(0.91,1.18) 
0.559 
(1.000) 
0.50 
rs12525353 6q25.1 C/A C 0.029 0.029 1.03 
(0.92,1.16) 
0.580 
(1.000) 
0.65 1.08 
(0.94,`.25) 
0.278 
(1.000) 
0.74 
rs1333049 9p21 G/C C 0.458 0.505 1.20 
(1.16,1.25) 
2.89x10
-21
 
(3.76x10
-20
) 
0.65 1.24 
(1.18,1.30) 
1.28x10
-18
 
(1.66x10
-17
) 
0.76 
rs10738610 9p21 A/C C 0.475 0.516 1.19 
(1.14,1.24) 
1.98x10
-17
 
(2.57x10
-16
) 
0.23 1.22 
(1.16,1.28) 
1.03x10
-14
 
(1.34x10
-13
) 
0.17 
rs501120 10q11.21 T/C T 0.133 0.121 1.11 
(1.05,1.18) 
4.34x10
-4
 
(5.64x10
-3
) 
0.04 1.15 
(1.07,1.24) 
1.99x10
-4
 
(2.59x10
-3
) 
0.07 
rs2146807 10q11.21 T/C T 0.122 0.117 1.02 
(0.96,1.09) 
0.453 
(1.000) 
0.95 1.01 
(0.94,1.08) 
0.844 
(1.000) 
0.99 
rs17228212 15q22.33 T/C T 0.276 0.274 1.00 
(0.95,1.04) 
0.893 
(1.000) 
0.11 1.02 
(0.97,1.07) 
0.521 
(1.000) 
0.13 
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Legend to Supplementary Table 3. SNP, single nucleotide polymorphism; chr, chromosome; + a2 is minor allele;  RA, risk allele; MAF, minor allele 
frequency; OR, odds ratio associated with the risk allele, based on a fixed effects logistic regression analysis adjusting for study and centre (for studies 
with multiple centres); CI, Confidence intervals. § p-value for heterogeneity between studies assessed  (see Statistical Methods). #Only one SNP, 
rs2972147, showed very strong heterogeneity, I2=72% in CAD, I2=71% in MI. Analysis of this SNP using a random effects model gave an OR for CAD of 
1.03 (0.95, 1.12) and for MI of 1.01 (0.92, 1.12). P-values in parentheses are after Bonferonni correction. The CIs have not been adjusted for multiple 
comparisons.
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Supplementary Table 4 Pooled association analysis for the six loci nominally significant in the present study with those from the two previous genome-
wide association studies   
 
 
  
 
 
 
 
 
 
 
 
 
 
 
*The previous GWA studies refer to the Wellcome Trust Case Control Consortium (WTCCC) study and the German MI Family Study. The pooled results 
from these studies have been taken from Supplementary Reference 6.  #P values for the previous GWA studies were Bonferroni corrected for the 
multiple (270,000) SNPs tested in these studies.     
SNP Previous GWA 
studies* 
Current studies Combined Combined with 
Bonferroni 
correction
#
 
rs599839 (1p13.3)) 4.05x10
-9
 1.44x10
-7
 1.09x10
-14
 1.97x10
-9
 
rs3008621 (1q41) 4.89x10
-6
 1.02x10
-3
 5.36x10
-8
 4.72x10
-3
 
rs2943634 (2q36.3) 1.61x10
-7
 3.22x10
-2
 5.56x10
-8
 6.27x10
-3
 
rs6922269 (6q25.1) 2.90x10
-8
 1.96x10
-2
 6.73x10
-9
 8.57x10
-4
 
rs1333049 (9p21) 2.90x10
-19
 2.89x10
-21
 3.87x10
-38
 9.30x10
-34
 
rs501120 (10q11.21) 9.46x10
-8
 4.34x10
-4
 5.40x10
-10
 7.65x10
-5
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Supplementary Table 5 Likelihood ratio test for a non-additive genetic model at each locus 
 
 
 
 
 
 
 
 
 
 
 
* P-values for males and females were 0.139 and 0.166 respectively 
 
 
 
 
 
SNP P-value 
rs599839 (1p13.3) 0.344 
rs3008621 (1q41) 0.859 
rs2943634 (2q36.3) 0.151 
rs6922269 (6q25.1) 0.339 
rs1333049 (9p21) 0.407 
rs501120 (10q11.21)* 0.070 
rs17228212 (15q22.33) 0.783 
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Supplementary Table 6 Probability (as percentage) that 0,1,…9 studies will be individually significant at the 5% level and the power of the pooled 
analysis for different combinations of per allele odds ratio (OR) and minor allele frequency (MAF) 
 
OR   1.05     1.10     1.15     1.20     1.25   
MAF 0.1 0.2 0.3 0.4 0.5 0.1 0.2 0.3 0.4 0.5 0.1 0.2 0.3 0.4 0.5 0.1 0.2 0.3 0.4 0.5 0.1 0.2 0.3 0.4 0.5 
0 50 41 34 29 27 19 5 2 1 1 3               
1 37 38 41 38 42 32 21 11 8 7 13 2    2          
2 11 16 18 25 22 31 29 22 20 20 25 8 2 2  8          
3 2 4 7 8 7 13 26 30 29 26 29 15 7 4 3 17 1    3     
4   1 1 2 5 14 20 23 23 20 27 16 15 10 25 6 2  1 11 1    
5      1 5 9 13 14 9 26 29 23 24 26 16 7 3 3 22 3    
6       1 4 5 7 2 15 26 26 30 16 27 16 11 11 29 7 3 1 1 
7         1 2  6 15 23 21 5 28 31 26 28 22 25 14 7 7 
8            1 5 7 9 1 16 30 40 35 11 41 37 34 35 
9             1 1 2  6 14 19 23 2 23 46 59 57 
Power 30 51 60 71 70 86 98 99 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 
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Supplementary Figure 1 
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BMI    <26
.           26+
Hypten No
.           Yes
Smoker No
.           Yes
Diabetes No
.              Yes
Subgroup
1.06 (0.99, 1.14)
1.19 (1.06, 1.33)
1.00 (0.91, 1.11)
1.15 (1.07, 1.24)
1.03 (0.93, 1.14)
1.13 (1.04, 1.24)
1.11 (1.00, 1.23)
1.05 (0.92, 1.19)
1.16 (1.01, 1.34)
1.11 (1.01, 1.21)
1.11 (1.03, 1.20)
1.21 (0.91, 1.60)
OR (95% CI)
  1.75 1.25 1.5
Male
Female
Age   <55
.          55+
BMI    <26
.           26+
Hypten No
.           Yes
Smoker No
.           Yes
Diabetes No
.              Yes
Subgroup
1.03 (0.98, 1.08)
1.06 (0.98, 1.15)
1.08 (1.00, 1.16)
1.02 (0.97, 1.08)
0.98 (0.92, 1.06)
1.04 (0.98, 1.11)
1.00 (0.93, 1.08)
1.04 (0.95, 1.14)
0.99 (0.90, 1.10)
1.04 (0.97, 1.11)
1.01 (0.95, 1.07)
1.03 (0.84, 1.26)
OR (95% CI)
  1.75 1.25 1.5
 
 
Male
Female
Age   <55
.          55+
BMI    <26
.           26+
Hypten No
.           Yes
Smoker No
.           Yes
Diabetes No
.              Yes
Subgroup
1.04 (0.98, 1.10)
1.08 (0.99, 1.17)
1.01 (0.94, 1.09)
1.06 (1.00, 1.12)
1.01 (0.94, 1.09)
1.10 (1.03, 1.18)
1.03 (0.95, 1.12)
1.06 (0.96, 1.17)
1.07 (0.96, 1.20)
1.08 (1.01, 1.16)
1.08 (1.01, 1.14)
0.98 (0.78, 1.23)
OR (95% CI)
  1.75 1.25 1.5
Male
Female
Age   <55
.          55+
BMI    <26
.           26+
Hypten No
.           Yes
Smoker No
.           Yes
Diabetes No
.              Yes
Subgroup
1.16 (1.11, 1.22)
1.29 (1.20, 1.39)
1.23 (1.15, 1.31)
1.20 (1.14, 1.26)
1.21 (1.13, 1.30)
1.19 (1.12, 1.26)
1.22 (1.13, 1.31)
1.10 (1.01, 1.20)
1.16 (1.05, 1.27)
1.18 (1.11, 1.26)
1.18 (1.12, 1.25)
1.12 (0.93, 1.35)
OR (95% CI)
  1.75 1.25 1.5
Male
Female
Age   <55
.          55+
BMI    <26
.           26+
Hypten No
.           Yes
Smoker No
.           Yes
Diabetes No
.              Yes
Subgroup
1.03 (0.96, 1.11)
1.29 (1.15, 1.45)
1.09 (0.98, 1.20)
1.14 (1.05, 1.23)
1.19 (1.07, 1.33)
1.10 (1.00, 1.20)
1.09 (0.97, 1.23)
1.12 (0.98, 1.28)
1.11 (0.96, 1.29)
1.06 (0.96, 1.17)
1.09 (1.00, 1.18)
1.17 (0.85, 1.60)
OR (95% CI)
  1.75 1.25 1.5
 
rs599839 on 1p13.3 rs3008621on 1q41 rs2943634 on 2q36.3 
rs6922269 on 6q25.1 
 
rs1333049 on 9p21 
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